Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study

American Heart Journal

Volumn 170, Issue 5, 2015, Pages 961-967

  Lazo, Mariana ^a,b   Halushka, Marc K ^a   Shen, Lu ^b   Maruthur, Nisa ^a,b   Rebholz, Casey M ^b   Rawlings, Andreea M ^b   Hoogeveen, Ron C ^c   Brinkley, Tina E ^d   Ballantyne, Christie M ^c   Astor, Brad C ^e   Selvin, Elizabeth ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLACK PERSON; BODY MASS; CARDIOVASCULAR RISK; DIABETES MELLITUS; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX DIFFERENCE; ATHEROSCLEROSIS; BLOOD; CLINICAL TRIAL; COMPLICATION; FOLLOW UP; FORECASTING; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; RISK FACTOR; UNITED STATES;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ATHEROSCLEROSIS; BIOMARKERS; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84954270822     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.08.008     Document Type: Article

References (29)

1. C. Piperi, C. Adamopoulos, G. Dalagiorgou, and et al. Crosstalk between advanced glycation and endoplasmic reticulum stress: emerging therapeutic targeting for metabolic diseases J Clin Endocrinol Metab 97 7 2012 2231 2242
2. S.F. Yan, R. Ramasamy, and A.M. Schmidt Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications Nat Clin Pract Endocrinol Metab 4 5 2008 285 293
3. A. Fukami, H. Adachi, S. Yamagishi, and et al. Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population Metabolism 58 12 2009 1688 1693
4. A.M. Schmidt, S.D. Yan, S.F. Yan, and et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses J Clin Invest 108 7 2001 949 955
5. S. Yamagishi Comment on: Selvin et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013;62:2116-2121 Diabetes 62 2013 2116 2121 [Diabetes 2013;62(10):e26]
6. M.B. Manigrasso, J. Juranek, R. Ramasamy, and et al. Unlocking the biology of RAGE in diabetic microvascular complications Trends Endocrinol Metab 25 1 2014 15 22
7. S.F. Yan, G.R. Barile, V. D'Agati, and et al. The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications Curr Diab Rep 7 2 2007 146 153
8. T. Wendt, E. Harja, L. Bucciarelli, and et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes Atherosclerosis 185 1 2006 70 77
9. E. Braunwald Biomarkers in heart failure N Engl J Med 358 20 2008 2148 2159
10. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators Am J Epidemiol 129 4 1989 687 702
11. J.K. Bower, J.S. Pankow, M. Lazo, and et al. Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE) Clin Biochem 47 1-2 2014 132 134
12. E. Selvin, M.K. Halushka, A.M. Rawlings, and et al. sRAGE and risk of diabetes, cardiovascular disease, and death Diabetes 62 6 2013 2116 2121
13. J.B. Lindsey, J.A. de Lemos, F. Cipollone, and et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study Diabetes Care 32 7 2009 1218 1220
14. M. Brownlee, A. Cerami, and H. Vlassara Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications N Engl J Med 318 20 1988 1315 1321
15. H.M. Colhoun, D.J. Betteridge, P. Durrington, and et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial Diabetes 60 9 2011 2379 2385
16. S.K. Agarwal, L.E. Chambless, C.M. Ballantyne, and et al. Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) Study Circ Heart Fail 5 4 2012 422 429
17. L.G. Bucciarelli, T. Wendt, W. Qu, and et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice Circulation 106 22 2002 2827 2835
18. L. Park, K.G. Raman, K.J. Lee, and et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts Nat Med 4 9 1998 1025 1031
19. R. Ramasamy, and A.M. Schmidt Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure Curr Heart Fail Rep 9 2 2012 107 116
20. S. Yamagishi, and T. Matsui Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker Front Biosci (Elite Ed) 2 2010 1184 1195
21. C. Falcone, E. Emanuele, A. D'Angelo, and et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men Arterioscler Thromb Vasc Biol 25 5 2005 1032 1037
22. L.J. Wang, L. Lu, F.R. Zhang, and et al. Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure Eur J Heart Fail 13 4 2011 440 449
23. R.D. Semba, L. Ferrucci, K. Sun, and et al. Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women Aging Clin Exp Res 21 2 2009 182 190
24. M.C. Thomas, J. Soderlund, M. Lehto, and et al. Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes Diabetologia 54 10 2011 2669 2677
25. Y. Koyama, Y. Takeishi, T. Niizeki, and et al. Soluble receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure J Card Fail 14 2 2008 133 139
26. S. Raposeiras-Roubin, B.K. Rodino-Janeiro, L. Grigorian-Shamagian, and et al. Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of Seattle Heart Failure Score Am J Cardiol 107 6 2011 938 944
27. M. Maruthur NL, M.K. Halushka, B.C. Astor, and et al. Genetics of sRAGE and cardiovascular outcomes in a community-based population PLoS One 10 6 2015 e0128452
28. W.D. Rosamond, P.P. Chang, C. Baggett, and et al. Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria Circ Heart Fail 5 2 2012 152 159
29. M.L. Hall, S. Levant, and C.J. DeFrances Hospitalization for congestive heart failure: United States, 2000-2010 NCHS Data Brief 2012